UPDATED: Novartis on Track to File Kymriah in R/R FL and 2L DLBCL in 2021; Meet the Management Investor Call Summary
Here is a brief preview of this blast: New content: The Celltelligence team has included and updated its CAR-T indications table for estimated approvals and submissions (see below for download) and made a small clarification that BELINDA trial results for Kymriah are expected at ASH 2021.